The MPN, however, are HSC disorders and JAK2V617F did not alter MPN HSC pool size nor did JAK2 inhibition significantly reduce the MPN HSC burden in animal [10] or human studies [11], suggesting mechanisms other than JAK2 activation are also involved in MPN pathophysiology. Here, JAK2 is linked to myeloproliferative neoplasm.